...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: National Kidney Foundation -Abstract: BOM

So the information ends up being post-hoc analysis for patients with T2D, CKD with <60 eGFR levels, receiving top standard of care with apabetalone vs top standard of care receiving a placebo. This hopefully will show an increase in the eGFR levels in the Apabetalone group compared with the placebo group.

 

Koo

Share
New Message
Please login to post a reply